Sequential treatment patterns over time for advanced renal cell carcinoma – Data from the German research platform CARAT. 3. August 2022 Goebell, P.J., Grüllich, C., Müller, L., Bögemann, M., Martens, U., von der Heyde, E., Reichert, D., Nusch, A., Schlenska-Lange., A., Wetzel, N., Koska, M., Jänicke, M., Marschner, N., Staehler, M., Grünwald, V., 2022. Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials. Dechow T, Aldaoud A, Behlendorf T, Knauf W, Eschenburg H, Groschek M, Hansen R, Söling U, Grebhardt S, Siebenbach HU, Vannier C, Potthoff K, 2022. Weiterlesen FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma – A novel validated prognostic score to facilitate treatment decision-making in real-world. Marschner N, Hegewisch-Becker S, Reiser M, von der Heyde E, Bertram M, Hollerbach SH, Kreher S, Wolf T, Binninger A, Chiabudini M, Kaiser-Osterhues A, Jänicke… Weiterlesen